DGAP-News
EVOTEC ACHIEVES MILESTONE IN ITS NEURODEGENERATION COLLABORATION WITH BRISTOL MYERS SQUIBB
DGAP-News: Evotec SE / Key word(s): Miscellaneous |
- ADDING ANOTHER DRUG DISCOVERY PROJECT TO THE PORTFOLIO TRIGGERS PAYMENT TO EVOTEC
Hamburg, Germany, 05 January 2021:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that the Company has received a US$ 6 m payment from
Bristol Myers Squibb Company (NYSE:BMY) within the companies' iPSC-based neuroscience partnership. The payment follows Bristol Myers Squibb's decision to add another drug discovery project to the
partnership's portfolio.
Evotec and Bristol Myers Squibb (the successor in interest to Celgene) initiated the collaboration in 2016 to identify disease-modifying treatments for a broad range of neurodegenerative
diseases. Currently approved drugs only offer short-term management of patients' symptoms and there is a huge unmet medical need for therapies that slow down or reverse disease progression in the
field of neurodegenerative diseases.
This collaboration pursues an innovative approach to the discovery and development of novel medicines by leveraging several of Evotec's unique technology platforms in conjunction with the human
iPSC-based platform, which is one of the largest and most sophisticated platforms in the industry. The partnership between Bristol Myers Squibb and Evotec has already found several access points
into neurodegenerative diseases and has to-date delivered a broad portfolio targeting key disease mechanisms in neurodegeneration.
Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "We are very excited about this most recent expansion of our joint project portfolio which further validates our iPSC-based
approach within our strategic neuroscience partnership with Bristol Myers Squibb. Our partnership with Bristol Myers Squibb is driven by the firm belief that iPSC-based approaches will deliver
more disease-relevant drug candidates which will have a better chance to deliver safe and effective drugs than traditional approaches."